Claya Review

What Claya charges

• Sermorelin: $199/mo — the product page prints "As low as $199/mo" beneath the benefit list
• NAD+: $199/mo — the product page prints "As low as $199/mo" beneath the benefit list

Two pharmacies, named, with addresses and phone numbers

The sitewide footer carries a partner-pharmacy block listing two facilities, each with a street address, a phone number and a web address.

That is the most complete answer to the pharmacy question anywhere in this comparison. Most sellers name nothing; a few name one; this one names two and tells a reader where they are.

The terms are equally direct about what the company is not, stating that it is not acting as a pharmacy and does not control how medication is provided.

The operating company and its state of incorporation are named in the same document, so there is an entity behind the brand a reader can look up.

A service-area commitment that is about the company

The terms state that the site and services are available in all fifty states plus the District of Columbia.

That sentence is about where the company sells. A separate sentence in the same document says consultations are provided by someone licensed in the state where the patient is located, which is a different fact about a different party.

This site sets the coverage flag on the first sentence and never on the second, because a licensure claim about clinicians has been used more than once in this market to imply a footprint the company does not have.

The same terms carry a Louisiana carve-out, and it is scoped to compounded GLP-1 medications rather than to either compound recorded here.

One figure, twice, with nothing to separate the two compounds

Both compounds sold here are priced on their own pages, and both carry the same starting figure phrased the same way.

Neither figure has a dose, a strength or a supply period attached, so a reader cannot tell what changes between them or what changes as a dose goes up.

They are two distinct compounds on two distinct pages rather than one product listed twice, so both are recorded — but the identical figure is a real limit on what the pages tell anybody.

The pages do say that no bloodwork is needed to get started, which settles the lab question in the opposite direction from inclusion.

The peptide pages are mostly about something else

Both product pages carry long stretches of weight-loss marketing, including a calculator that estimates weight loss from clinical trials of two drugs neither page is selling.

The compound-specific content is real and reasonably detailed, but it is interleaved with material that has nothing to do with either peptide.

A reader skimming for a figure will pass several that belong to a different product line entirely before reaching the one that belongs to this compound.

The figure recorded here was taken from the block that sits under the compound's own benefit list, not from anything in the surrounding marketing.

How we verified this

• Rendered both product pages in a browser and took each figure from the block beneath that compound's own benefit list.
• Fired two nonsense paths at this host in the same pass, one of them under the peptides directory, and confirmed both render the same genuine not-found document.
• Read the sitewide footer on more than one page to confirm the partner-pharmacy block appears throughout rather than on one template.
• Read the terms in full for a service-area sentence and set the coverage flag on the one describing the company, not on the separate sentence about where its providers are licensed.
• Checked the scope of the Louisiana carve-out in the same terms and confirmed it names compounded GLP-1 medications rather than either compound recorded here.
• Read the terms for the operating company and its state of incorporation rather than assuming the brand is the entity.
• Confirmed that the two compounds are sold on two separate pages, rather than recording one product twice under different names.
• Read the three-step summary on the product page for the lab question and recorded the seller's own statement that no bloodwork is needed to start.
• Screened this seller in the live federal warning-letter record by brand and by operating company, with a known-good positive control and a nonsense negative control fired in the same run.
• Read the company column of every returned record rather than accepting a full-text match, and attached no letter on a name match.